Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

被引:3
作者
Chun, Min Young [1 ,2 ,3 ]
Jang, Hyemin [1 ,4 ,5 ]
Kim, Hee Jin [1 ,5 ,6 ,7 ]
Kim, Jun Pyo [1 ,8 ]
Gallacher, John [9 ]
Allue, Jose Antonio [10 ]
Sarasa, Leticia [10 ]
Castillo, Sergio [10 ]
Pascual-Lucas, Maria L. [10 ]
Na, Duk [1 ,5 ]
Seo, Sang Won [1 ,5 ,6 ,7 ,11 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea
[2] Yonsei Univ, Dept Neurol, Coll Med, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Yongin Severance Hosp, Dept Neurol, Yongin, South Korea
[4] Samsung Med Ctr, Neurosci Ctr, Seoul, South Korea
[5] Samsung Med Ctr, Alzheimers Dis Convergence Res Ctr, Seoul, South Korea
[6] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea
[7] Sungkyunkwan Univ, Dept Digital Hlth, SAIHST, Seoul, South Korea
[8] Indiana Univ Sch Med, Ctr Neuroimaging Radiol & Imaging Sci, Indianapolis, IN USA
[9] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
[10] Araclon Biotech Grifols, Zaragoza, Spain
[11] Sungkyunkwan Univ, Dept Clin Res Design & Evaluat, SAIHST, Seoul, South Korea
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Alzheimer's disease; beta-Amyloid; positron emission tomography; cerebrospinal fluid; plasma; apolipoprotein E; ALZHEIMERS ASSOCIATION WORKGROUPS; CEREBROSPINAL-FLUID BIOMARKERS; CENTRAL-NERVOUS-SYSTEM; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; APOLIPOPROTEIN-E; DISEASE; PET; IMPAIRMENT; RECOMMENDATIONS;
D O I
10.3389/fnagi.2023.1126799
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: Early detection of beta-amyloid (A beta) accumulation, a major biomarker for Alzheimer's disease (AD), has become important. As fluid biomarkers, the accuracy of cerebrospinal fluid (CSF) A beta for predicting A beta deposition on positron emission tomography (PET) has been extensively studied, and the development of plasma A beta is beginning to receive increased attention recently. In the present study, we aimed to determine whether APOE genotypes, age, and cognitive status increase the predictive performance of plasma A beta and CSF A beta levels for A beta PET positivity. Methods: We recruited 488 participants who underwent both plasma A beta and A beta PET studies (Cohort 1) and 217 participants who underwent both cerebrospinal fluid (CSF) A beta and A beta PET studies (Cohort 2). Plasma and CSF samples were analyzed using ABtest-MS, an antibody-free liquid chromatography-differential mobility spectrometry-triple quadrupole mass spectrometry method and INNOTEST enzyme-linked immunosorbent assay kits, respectively. To evaluate the predictive performance of plasma A beta and CSF A beta, respectively, logistic regression and receiver operating characteristic analyses were performed. Results: When predicting A beta PET status, both plasma A beta 42/40 ratio and CSF A beta 42 showed high accuracy (plasma A beta area under the curve (AUC) 0.814; CSF A beta AUC 0.848). In the plasma A beta models, the AUC values were higher than plasma A beta alone model, when the models were combined with either cognitive stage (p<0.001) or APOE genotype (p=0.011). On the other hand, there was no difference between the CSF A beta models, when these variables were added. Conclusion: Plasma A beta might be a useful predictor of A beta deposition on PET status as much as CSF A beta, particularly when considered with clinical information such as APOE genotype and cognitive stage.
引用
收藏
页数:9
相关论文
共 57 条
  • [1] Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients
    Ahn, Hyun-Jung
    Chin, Juhee
    Park, Aram
    Lee, Byung Hwa
    Suh, Mee Kyung
    Seo, Sang Won
    Na, Duk L.
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (07) : 1071 - 1076
  • [2] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    Albert, Marilyn S.
    DeKosky, Steven T.
    Dickson, Dennis
    Dubois, Bruno
    Feldman, Howard H.
    Fox, Nick C.
    Gamst, Anthony
    Holtzman, David M.
    Jagust, William J.
    Petersen, Ronald C.
    Snyder, Peter J.
    Carrillo, Maria C.
    Thies, Bill
    Phelps, Creighton H.
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (03) : 270 - 279
  • [3] The accuracy and robustness of plasma biomarker models for amyloid PET positivity
    Benedet, Andrea L.
    Brum, Wagner S.
    Hansson, Oskar
    Initiative, Alzheimer's Disease Neuroimaging
    Karikari, Thomas K.
    Zimmer, Eduardo R.
    Zetterberg, Henrik
    Blennow, Kaj
    Ashton, Nicholas J.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [4] Amyloid biomarkers in Alzheimer's disease
    Blennow, Kai
    Mattsson, Niklas
    Scholl, Michael
    Hansson, Oskar
    Zetterberg, Henrik
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (05) : 297 - 309
  • [5] Blood-brain barrier impairment in Alzheimer disease - Stability and functional significance
    Bowman, G. L.
    Kaye, J. A.
    Moore, M.
    Waichunas, D.
    Carlson, N. E.
    Quinn, J. F.
    [J]. NEUROLOGY, 2007, 68 (21) : 1809 - 1814
  • [6] Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults
    Bowman, Gene L.
    Dayon, Loic
    Kirkland, Richard
    Wojcik, Jerome
    Peyratout, Gwendoline
    Severin, India C.
    Henry, Hugues
    Oikonomidi, Aikaterini
    Migliavacca, Eugenia
    Bacher, Michael
    Popp, Julius
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (12) : 1640 - 1650
  • [7] Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
    Burnham, Samantha C.
    Fandos, Noelia
    Fowler, Christopher
    Perez-Grijalba, Virginia
    Dore, Vincent
    Doecke, James D.
    Shishegar, Rosita
    Cox, Timothy
    Fripp, Jurgen
    Rowe, Christopher
    Sarasa, Manuel
    Masters, Colin L.
    Pesini, Pedro
    Villemagne, Victor L.
    [J]. BRAIN COMMUNICATIONS, 2020, 2 (01)
  • [8] Role of Blood-Brain Barrier in Alzheimer's Disease
    Cai, Zhiyou
    Qiao, Pei-Feng
    Wan, Cheng-Qun
    Cai, Min
    Zhou, Nan-Kai
    Li, Qin
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (04) : 1223 - 1234
  • [9] Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid
    Cho, Soo Hyun
    Choe, Yeong Sim
    Park, Seongbeom
    Kim, Young Ju
    Kim, Hee Jin
    Jang, Hyemin
    Kim, Seung Joo
    Kim, Jun Pyo
    Jung, Young Hee
    Kim, Byeong C.
    Na, Duk L.
    Moon, Seung Hwan
    Seo, Sang Won
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB
    Cho, Soo Hyun
    Choe, Yeong Sim
    Kim, Hee Jin
    Jang, Hyemin
    Kim, Yeshin
    Kim, Si Eun
    Kim, Seung Joo
    Kim, Jun Pyo
    Jung, Young Hee
    Kim, Byeong C.
    Baker, Suzanne L.
    Lockhart, Samuel N.
    Na, Duk L.
    Park, Seongbeom
    Seo, Sang Won
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (08) : 1938 - 1948